Detalles de la búsqueda
1.
Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices.
Ann Hematol
; 103(5): 1569-1575, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38472361
2.
Treatment-Free Remission in Real-World Chronic Myeloid Leukemia Patients: Insights from German Hematology Practices.
Acta Haematol
; 145(6): 603-610, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35908542
3.
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
Haematologica
; 104(5): 955-962, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30514803
4.
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Ann Intern Med
; 168(7): 461-470, 2018 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29459949
5.
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.
Blood
; 124(26): 3870-9, 2014 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-25359988
6.
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.
Ann Hematol
; 94(12): 2015-24, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26385387
7.
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
Haematologica
; 99(9): 1441-7, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24837466
8.
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.
Ann Hematol
; 93(1): 71-80, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24162333
9.
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
J Clin Oncol
; : JCO2301647, 2024 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38471049
10.
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Leukemia
; 38(2): 318-325, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38129513
11.
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.
Blood Adv
; 2(13): 1572-1579, 2018 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29980572
12.
Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.
Clin Lymphoma Myeloma Leuk
; 18(4): 266-271, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29510895
13.
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
J Clin Oncol
; 32(5): 415-23, 2014 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24297946
Resultados
1 -
13
de 13
1
Próxima >
>>